Hearing thresholds at high frequency in patients with cystic fibrosis: a systematic review

Introduction High-frequency audiometry may contribute to the early detection of hearing loss caused by ototoxic medications. Many ototoxic drugs are widely used in the treatment of patients with cystic fibrosis. Early detection of hearing loss should allow known harmful drugs to be identified before the damage affects speech frequencies. The damage caused by ototoxicity is irreversible, resulting in important social and psychological consequences. In children, hearing loss, even when restricted to high frequencies, can affect the development of language. Objective To investigate the efficacy and effectiveness of hearing monitoring through high-frequency audiometry in pediatric patients with cystic fibrosis. Methods Electronic databases PubMed, MedLine, Web of Science and LILACS were searched, from January to November 2015. The selected studies included those in which high-frequency audiometry was performed in patients with cystic fibrosis, undergoing treatment with ototoxic drugs and published in Portuguese, English and Spanish. The GRADE system was chosen for the evaluation of the methodological quality of the articles. Results During the search process carried out from January 2015 to November 2015, 512 publications were identified, of which 250 were found in PubMed, 118 in MedLine, 142 in Web of Science and 2 in LILACS. Of these, nine articles were selected. Conclusion The incidence of hearing loss was identified at high frequencies in cystic fibrosis patients without hearing complaints. It is assumed that high-frequency audiometry can be an early diagnostic method to be recommended for hearing investigation of patients at risk of ototoxicity.

• Publication year

  2016

• Venue

  Brazilian Journal of Otorhinolaryngology

• Publication date

  2016-11-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bjorl.2016.10.006PMID 27894912PMCID 9442726
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review

  2016cited by this paper
• High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients

  2015cited by this paper
• High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.

  2015cited by this paper
• Avaliação do uso da audiometria em frequências ultra-altas em pacientes submetidos ao uso de ototóxicos

  2013cited by this paper
• Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Audiometria de altas frequências no diagnóstico complementar em audiologia: uma revisão da literatura nacional

  2011cited by this paper
• Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions

  2011influential reference
• Hearing loss in cystic fibrosis.

  2010cited by this paper
• Aminoglycoside ototoxicity susceptibility in cystic fibrosis

  2009cited by this paper
• Cystic Fibrosis

  2009cited by this paper
• GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

  2008cited by this paper
• Going from evidence to recommendations

  2008cited by this paper
• Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population

  2008cited by this paper
• Estudo audiometrico de alta fraquncia em pacientes curados de cncer tratados com cisplatina

  2008cited by this paper
• Manifestações otorrinolaringológicas da fibrose cística: revisão da literatura

  2008influential reference
• Diagnóstico e tratamento das Bronquiectasias: uma atualização

  2007cited by this paper
• A prevalência de perdas auditivas em crianças e adolescentes com câncer

  2007cited by this paper
• Limiares audiométricos de altas frequências em pacientes com diabetes mellitus insulino-dependente

  2006cited by this paper
• Auditory monitoring in ototoxicity.

  2006cited by this paper
• Absence of Cochleotoxicity Measured by Standard and High-Frequency Pure Tone Audiometry in a Trial of Once- versus Three-Times-Daily Tobramycin in Cystic Fibrosis Patients

  2006cited by this paper
• Changes in otoacoustic emissions and high-frequency hearing thresholds in children and adolescents.

  2006cited by this paper
• Normal nasal mucociliary clearance in CF children: evidence against a CFTR‐related defect

  2004cited by this paper
• Molecular classification of lung cancer: a cross-platform comparison of gene expression data sets.

  2004cited by this paper
• Grading quality of evidence and strength of recommendations

  2004cited by this paper
• Cystic fibrosis adult care: consensus conference report.

  2004cited by this paper
• The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Clínicas de Porto Alegre.

  2003cited by this paper
• Monitoramento da audição de pacientes expostos à cisplatina

  2003cited by this paper
• [Controversies in cystic fibrosis--from pediatrician to specialist].

  2002cited by this paper
• [High-frequency audiometry: hearing thresholds in normal ears].

  2001influential reference
• High frequency audiometry and chronic renal failure.

  2001cited by this paper
• Occurrence and Risk of Cochleotoxicity in Cystic Fibrosis Patients Receiving Repeated High-Dose Aminoglycoside Therapy

  2001cited by this paper
• Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

  1999cited by this paper
• Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa.

  1999cited by this paper
• The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.

  1998cited by this paper
• Cystic fibrosis.

  1993cited by this paper
• Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.

  1989cited by this paper
• Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis

  1987cited by this paper
• Cystic fibrosis in the Netherlands.

  1977cited by this paper
• Cystic fibrosis in the Netherlands

  1977cited by this paper
• GrADE: an emerging consensus on rating quality of evidence and strength of recommendations

  year unknowncited by this paper

• HOW THE SPEECH-LANGUAGE PATHOLOGIST INTERACTS WITH CYSTIC FIBROSIS PATIENTS? A SCOPING REVIEW

  2023cites this paper
• Hearing Impairment in the Extended High Frequencies in Children Despite Clinically Normal Hearing

  2022cites this paper
• Extended High-Frequency Audiometry for Ototoxicity Monitoring: A Longitudinal Evaluation of Drug-Resistant Tuberculosis Treatment.

  2022cites this paper
• Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.

  2020cites this paper
• Exploration fonctionnelle auditive

  2019cites this paper
• Erratum of “Hearing thresholds at high frequency in patients with cystic fibrosis: a systematic review”

  2017cites this paper